SPRYARS Pharmaceuticals Inc
SPRY
ARS Pharmaceuticals Inc2,450
Mkt Cap
$788.42MVolume
1.62M52W High
$18.9052W Low
$6.66PE Ratio
-4.57SPRY Fundamentals
Price
$7.65Prev Close
$7.94Open
$7.5650D MA
$8.33Beta
1.25Avg. Volume
1.53MEPS (Annual)
-$1.74P/B
6.90Rev/Employee
$517,042.95$1,000.28
Compact View
Not available
Not available
Earnings Recap
• Reported GAAP EPS of -$0.61 down -74.29% YoY • Reported revenue of $22.68M up 184.47% YoY
Bullish
ARS Pharmaceuticals Inc. demonstrates strong commercial momentum for nef y, driven by broad global regulatory approvals, increasing patient adoption, and expanding insurance coverage across key markets.
Bearish
ARS Pharmaceuticals Inc. faces significant commercialization uncertainty for nef y, intense competition from potentially superior products, and costly patent infringement lawsuits from generic competitors.